CSL News: Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis - 7th Feb 2023, 9:00am

[annb0t]

First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced the Therapeutic Goods Administration (TGA) in Australia has approved Tavneos® in combination with a rituximab or cyclophosphamide-based regimen for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA) – associate...

>>> Read more: Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis